MTOR and diabetic kidney disease: Dysregulation of the antagonistic interplay between the mechanistic target of rapamycin (mTOR) and AMP-activated protein kinase signaling pathways impairs mitochondrial quality control, contributing to the pathogenesis of AKI and diabetic nephropathy through disrupted cellular homeostasis [53].